Indication
Sintilimab and Anlotinib in Combination With Chemotherapy
1 clinical trial
1 product
Clinical trial
A Prospective Single-center, Single-arm, Open-label Study of Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal CancerStatus: Completed, Estimated PCD: 2022-04-01